SCHEMBL6635396

SCHEMBL6635396

COc1ccc(Cn2ncnc2SSc2ncnn2Cc2ccc(OC)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.52
NPSR1 Q6W5P4 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
NPBWR1 P48145 5/20 0.46
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALOX15 P16050 1/20 0.44
CMA1 P23946 1/20 0.44
LMNA P02545 2/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
MCHR1 Q99705 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
PDE1B Q01064 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12597291 0.81 ALDH1A1 (0.50) HTTSMN1; SMN2NPBWR1ALDH1A1MAPT
SCHEMBL30992791 0.81 NPBWR1 (0.51) SMN1; SMN2NPBWR1ALDH1A1MAPTKDM4E
SCHEMBL16014712 0.79 NPBWR1 (0.47) HTTNPSR1L3MBTL1SMN1; SMN2NPBWR1
SCHEMBL3296364 0.77 NPBWR1 (0.45) SMN1; SMN2NPBWR1ALDH1A1MAPTKDM4E
SCHEMBL7480360 0.77 NPBWR1 (0.45) NPSR1SMN1; SMN2NPBWR1ALDH1A1MAPT
SCHEMBL3296219 0.75 TAAR1 (0.51) SMN1; SMN2NPBWR1ALDH1A1MAPTKDM4E
SCHEMBL3296213 0.75 ALDH1A1 (0.43) NPSR1L3MBTL1SMN1; SMN2NPBWR1ALDH1A1
SCHEMBL29208868 0.72 ALDH1A1 (0.47) NPSR1SMN1; SMN2NPBWR1ALDH1A1MAPT
SCHEMBL30402448 0.72 ALDH1A1 (0.47) NPSR1SMN1; SMN2NPBWR1ALDH1A1MAPT
SCHEMBL8445010 0.71 DAO (0.53) HTTNPSR1L3MBTL1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280806-B1 THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2004-08-04 EP disclosed
US-20040014634-A1 Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals ASTRAZENECA AB (SE) 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014634-A1 Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals DPYD, TYMP, TYMS HTT 3802/4885NPSR1 1466/4885L3MBTL1 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.